Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
3,703 stopped studies mapped to Carcinoma and descendants · 91% state a reason
Over the 3,703 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05400122 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming… | Phase 1 | suspended | Jun 1, 2022 | David Wald | Drugs unavailable | Other (stated, no rule matched) |
| NCT06538389 | High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced… | Phase 2 | suspended | Aug 5, 2024 | City of Hope Medical Center | Accrual goal met | Enrollment / accrual |
| NCT02200042 | Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable… | Phase 3 | terminated | Jul 25, 2014 | NRG Oncology | not stated | Not stated |
| NCT04933695 | A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a…(CodeBreaK201) | Phase 2 | terminated | Jun 22, 2021 | Amgen | Futility | Efficacy / futility |
| NCT05067777 | Massage for Prostate Cancer-Related Fatigue (mPROSTATE)(mPROSTATE) | Phase 2 | terminated | Oct 5, 2021 | University of Utah | Lack of Funding | Funding |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2022 | TCR2 Therapeutics | No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear… | Enrollment / accrual |
| NCT03114319 | Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Apr 14, 2017 | Novartis Pharmaceuticals | Business reasons and not due to any safety concerns | Safety / toxicity |
| NCT03946423 | BAriaTric Surgery After Breast Cancer Treatment (BATS) | N/A | withdrawn | May 10, 2019 | Masonic Cancer Center, University of Minnesota | Not moving forward with study. | Other (stated, no rule matched) |
| NCT04331067 | Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast… | Phase 1 / Phase 2 | terminated | Apr 2, 2020 | Washington University School of Medicine | BMS terminated the study | Other (stated, no rule matched) |
| NCT04568304 | A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a… | Phase 3 | withdrawn | Sep 29, 2020 | Shanghai Junshi Bioscience Co., Ltd. | This study was not conducted | Other (stated, no rule matched) |
| NCT05705791 | Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial…(HOLMBRAVE) | N/A | terminated | Jan 31, 2023 | Gustave Roussy, Cancer Campus, Grand Paris | Toxicities | Safety / toxicity |
| NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… | Phase 1 | terminated | Sep 5, 2024 | BeOne Medicines | The Sponsor has made the decision to terminate this study due to the lack of promising efficacy,… | Efficacy / futility |
| NCT04216472 | Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple… | Phase 2 | terminated | Jan 2, 2020 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04585477 | Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) | Phase 2 | suspended | Oct 14, 2020 | Stanford University | pending protocol amendment | Other (stated, no rule matched) |
| NCT06466187 | A Study of SGN-MesoC2 in Advanced Solid Tumors | Phase 1 | terminated | Jun 20, 2024 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
| NCT04809766 | Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic… | Phase 1 | terminated | Mar 22, 2021 | Fred Hutchinson Cancer Center | Study terminated due to end of funding. | Funding |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating… | Phase 2 | terminated | Jun 6, 2013 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT04273555 | Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients… | Phase 1 / Phase 2 | withdrawn | Feb 18, 2020 | University of Alabama at Birmingham | Unable to recruit for this study. | Enrollment / accrual |
| NCT05571839 | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors | Phase 1 | terminated | Oct 7, 2022 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns. | Safety / toxicity |
| NCT05967533 | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With… | Phase 1 | suspended | Aug 1, 2023 | University of California, Davis | For internal interim analysis | Efficacy / futility |
| NCT05101356 | A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab… | Phase 1 / Phase 2 | suspended | Nov 1, 2021 | University of California, Davis | Drugs unavailable | Other (stated, no rule matched) |
| NCT06191250 | --SuPERIOR Trial-- | Phase 2 | terminated | Jan 5, 2024 | University Health Network, Toronto | Study Terminated Prior to trial activation, due to changes in SOC of the treatment | Other (stated, no rule matched) |
| NCT03139058 | Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of…(fibr'HOM) | N/A | terminated | May 3, 2017 | Centre Hospitalier Universitaire, Amiens | Recruitment difficulties | Enrollment / accrual |
| NCT04251715 | mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With… | Phase 2 | terminated | Feb 5, 2020 | OHSU Knight Cancer Institute | change in standard-of-care systemic therapy | Other (stated, no rule matched) |
| NCT05050162 | Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation… | Phase 2 / Phase 3 | suspended | Sep 20, 2021 | NRG Oncology | End of Initial Phase of Multi-phase protocol; closed for protocol specified analysis | Other (stated, no rule matched) |
| NCT07100925 | A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk… | Phase 1 | withdrawn | Aug 3, 2025 | Ankyra Therapeutics, Inc | Strategic realignment | Sponsor / business decision |
| NCT07136493 | Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With… | N/A | withdrawn | Aug 22, 2025 | City of Hope Medical Center | Funding This study has been closed at City of Hope at the request of the Sponsor due to delays and… | Funding |
| NCT03630640 | Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation(NIVOLEP) | Phase 2 | terminated | Aug 15, 2018 | Assistance Publique - Hôpitaux de Paris | Because patient recruitment was affected by the COVID-19 pandemic, the study sponsor and funding… | COVID-19 / pandemic |
| NCT00520975 | Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses… | Phase 3 | terminated | Aug 27, 2007 | National Cancer Institute (NCI) | Closed early due to slow accrual | Enrollment / accrual |
| NCT03353428 | Intervention of Engineered Immune Effector T Cells Against Lung Cancer | Phase 1 / Phase 2 | withdrawn | Nov 27, 2017 | Shenzhen Geno-Immune Medical Institute | combine with NCT03356808 | Other (stated, no rule matched) |
| NCT04346225 | Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in… | Phase 2 | suspended | Apr 15, 2020 | Ivan de Kouchkovsky, MD | Due to funding | Funding |
| NCT07216833 | Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell… | Phase 1 | withdrawn | Oct 15, 2025 | Case Comprehensive Cancer Center | PI leaving the institution | Other (stated, no rule matched) |
| NCT07524257 | Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care… | Phase 3 | withdrawn | Apr 13, 2026 | ImmunityBio, Inc. | Sponsor decision | Sponsor / business decision |
| NCT07570966 | Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients… | Phase 1 / Phase 2 | withdrawn | May 6, 2026 | Novartis Pharmaceuticals | Business decision | Sponsor / business decision |
| NCT04975516 | Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for… | Phase 2 | terminated | Jul 23, 2021 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT05130255 | GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 | Phase 1 | terminated | Nov 23, 2021 | Y-mAbs Therapeutics | Decision by Sponsor | Other (stated, no rule matched) |
| NCT05514717 | A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | Phase 1 | terminated | Aug 24, 2022 | Day One Biopharmaceuticals, Inc. | Development discontinued. | Other (stated, no rule matched) |
| NCT05537402 | LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC(LOST-B) | Phase 2 | terminated | Sep 13, 2022 | University of Texas Southwestern Medical Center | The decision was made to close the study to enrollment due to poor overall accrual and the… | Enrollment / accrual |
| NCT02626312 | Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma,… | Phase 1 | terminated | Dec 10, 2015 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT03631199 | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy…(CANOPY-1) | Phase 3 | terminated | Aug 15, 2018 | Novartis Pharmaceuticals | Results of primary analysis showed addition of canakinumab to combination treatment did not improve… | Safety / toxicity |
| NCT04158635 | Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic… | Phase 1 | suspended | Nov 12, 2019 | City of Hope Medical Center | Accrual Goal met | Enrollment / accrual |
| NCT06902246 | Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma | Phase 2 | withdrawn | Mar 30, 2025 | University of Miami | Investigator decision | Investigator |
| NCT03318939 | Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20… | Phase 2 | terminated | Oct 24, 2017 | Spectrum Pharmaceuticals, Inc | Strategic business decision (unrelated to safety) | Safety / toxicity |
| NCT04984811 | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally… | Phase 2 | terminated | Aug 2, 2021 | NeoImmuneTech | sponsor decision (not for safety) | Safety / toxicity |
| NCT05991752 | Health-Economic Evaluation of Early Diagnosis of Epithalial Ovarian Cancer Recurrence…(ROMECO) | N/A | withdrawn | Aug 15, 2023 | University Hospital, Tours | feasibility issue | Other (stated, no rule matched) |
| NCT05929664 | Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell… | Phase 2 | suspended | Jul 3, 2023 | Thomas Jefferson University | Investigational product is not currently available to the study site. | Other (stated, no rule matched) |
| NCT06267001 | A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in…(SKYSCRAPER-15) | Phase 3 | terminated | Feb 20, 2024 | Hoffmann-La Roche | Decision to terminate study was driven by results from preceding tiragolumab study… | Safety / toxicity |
| NCT04906369 | Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring | — | suspended | May 28, 2021 | Mayo Clinic | lack of funding | Funding |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In… | Phase 2 | terminated | Jun 7, 2021 | Regeneron Pharmaceuticals | Sponsor Decision related to study drug supply | Drug supply |
| NCT04994977 | Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid… | Phase 1 | terminated | Aug 6, 2021 | Weill Medical College of Cornell University | Study terminated due to low accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 14, 2026source: clinicaltrials